Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04338776 · ClinicalTrials.gov registry record · NA
Comparing UroLift Experience Against Rezūm
A NA study of Benign Prostatic Hyperplasia, sponsored by NeoTract.
- Active
- Registry status
- NA
- Development phase
- 120
- Enrollment target
- 10
- Study locations
NCT04338776: Active NA study of Benign Prostatic Hyperplasia, sponsored by NeoTract.
NCT04338776 is a NA study of Benign Prostatic Hyperplasia that is active but no longer recruiting, run by NeoTract. The registered enrollment target is 120 participants, below the 548-participant average among 29 other Benign Prostatic Hyperplasia trials with a reported enrollment target (78% lower). The trial reports 10 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04338776, a NA study of Benign Prostatic Hyperplasia, is active but no longer recruiting, sponsored by NeoTract.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
- 10
- Study locations
Study Summary
C.L.E.A.R. Study is poised to compare the patient experience post procedure, including catheterization needs as well as retreatment and BPH medication rates following treatment with either the UroLift® System or Rezūm™ System through 12 months.
Primary Outcome
Number of subjects who are catheter independent and remain catheter independent through 1-week
Conditions Studied
Interventions
- DEVICE UroLift
- DEVICE Rezum
Study Locations (10)
Texas
- Urology Austin - Austin
- UT Southwestern Medical Center - Dallas
- Urology San Antonio - San Antonio
New York
- NYU Winthrop Urology - Garden City
- Weil Cornell Medical College, Cornell University - New York
California
- Tower Urology - Los Angeles
Michigan
- Comprehensive Urology - Royal Oak
Camberley
- Frimley Park Hospital - Frimley
Norfolk
- NORFOLK and Norwich University Hospital - Norwich
Other
- Cambridge University Hospitals NHS Foundation Trust - Cambridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2021-01-22 |
| Est. Completion | 2025-12 |
| Phase | NA |
What the registry record for NCT04338776 still lists
NCT04338776 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 548-participant average among 29 other Benign Prostatic Hyperplasia trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Benign Prostatic Hyperplasia appearing as the primary indexed condition, and to 2 interventions - of which UroLift is the first listed.
NCT04338776 lists 10 locations in 7 states (Texas, New York, California).
Frequently Asked Questions
What is clinical trial NCT04338776 about?
NCT04338776 is a clinical study titled "Comparing UroLift Experience Against Rezūm". C.L.E.A.R. Study is poised to compare the patient experience post procedure, including catheterization needs as well as retreatment and BPH medication rates following treatment with either the UroLift® System or Rezūm™ System through 12 months.
What is the current status of trial NCT04338776?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2021-01-22. Estimated completion is 2025-12.
What conditions does trial NCT04338776 study?
This clinical trial studies the following conditions: Benign Prostatic Hyperplasia.
What interventions are being tested in trial NCT04338776?
The interventions under investigation include: UroLift (DEVICE), Rezum (DEVICE).
Who is sponsoring clinical trial NCT04338776?
This trial is sponsored by NeoTract, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04338776 being conducted?
This trial has 10 study locations across California, Michigan, New York, Texas, Camberley. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Benign Prostatic Hyperplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04338776's enrollment target sits among peer trials
120 18th of 29 higher than 11 of 29 other Benign Prostatic Hyperplasia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Benign Prostatic Hyperplasia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ambulatory Long Length URodynamics Evaluation
RECRUITING · NA
-
Safety and Effectiveness of the Optilume® BPH Catheter System in a Post-Market Study
RECRUITING · NA
-
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
RECRUITING · NA
-
A Clinical Study to Evaluate the Safety and Efficacy of the FloStent in Men With Benign Prostatic Hyperplasia Symptoms
RECRUITING · NA
-
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy
RECRUITING · NA
-
PRescription Exercise for Older Men With Urinary Disease
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI